PortalPublikationenAllogenic hematopoietic stem-cell transplantation with reduc...

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

Standard

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. / Shimoni, Avichai; Hardan, Izhar; Ayuketang Ayuk, Francis; Schilling, Georgia; Atanackovic, Djordje; Zeller, Wolfgang; Yerushalmi, Ronit; Zander, Axel R.; Kröger, Nicolaus; Nagler, Arnon.

in: CANCER-AM CANCER SOC, Jahrgang 116, Nr. 15, 15, 2010, S. 3621-3630.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Shimoni, A, Hardan, I, Ayuketang Ayuk, F, Schilling, G, Atanackovic, D, Zeller, W, Yerushalmi, R, Zander, AR, Kröger, N & Nagler, A 2010, 'Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.', CANCER-AM CANCER SOC, Jg. 116, Nr. 15, 15, S. 3621-3630. <http://www.ncbi.nlm.nih.gov/pubmed/20564132?dopt=Citation>

APA

Shimoni, A., Hardan, I., Ayuketang Ayuk, F., Schilling, G., Atanackovic, D., Zeller, W., Yerushalmi, R., Zander, A. R., Kröger, N., & Nagler, A. (2010). Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. CANCER-AM CANCER SOC, 116(15), 3621-3630. [15]. http://www.ncbi.nlm.nih.gov/pubmed/20564132?dopt=Citation

Vancouver

Shimoni A, Hardan I, Ayuketang Ayuk F, Schilling G, Atanackovic D, Zeller W et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. CANCER-AM CANCER SOC. 2010;116(15):3621-3630. 15.

Bibtex

@article{10ebb6417fa14d6482162c02141a5264,
title = "Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.",
abstract = "Allogeneic stem cell transplantation (SCT) with myeloablative conditioning is potentially curative therapy for myeloma, but is reportedly associated with a high risk of nonrecurrence mortality (NRM). Reduced-intensity conditioning (RIC) allows for the reduction of NRM, but the recurrence rate is increased. The role and timing of allogeneic SCT in the disease course remains controversial. To the authors' knowledge, there are limited data regarding the long-term outcome of RIC in the recurrent/refractory setting.",
author = "Avichai Shimoni and Izhar Hardan and {Ayuketang Ayuk}, Francis and Georgia Schilling and Djordje Atanackovic and Wolfgang Zeller and Ronit Yerushalmi and Zander, {Axel R.} and Nicolaus Kr{\"o}ger and Arnon Nagler",
year = "2010",
language = "Deutsch",
volume = "116",
pages = "3621--3630",
journal = "CANCER-AM CANCER SOC",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

RIS

TY - JOUR

T1 - Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

AU - Shimoni, Avichai

AU - Hardan, Izhar

AU - Ayuketang Ayuk, Francis

AU - Schilling, Georgia

AU - Atanackovic, Djordje

AU - Zeller, Wolfgang

AU - Yerushalmi, Ronit

AU - Zander, Axel R.

AU - Kröger, Nicolaus

AU - Nagler, Arnon

PY - 2010

Y1 - 2010

N2 - Allogeneic stem cell transplantation (SCT) with myeloablative conditioning is potentially curative therapy for myeloma, but is reportedly associated with a high risk of nonrecurrence mortality (NRM). Reduced-intensity conditioning (RIC) allows for the reduction of NRM, but the recurrence rate is increased. The role and timing of allogeneic SCT in the disease course remains controversial. To the authors' knowledge, there are limited data regarding the long-term outcome of RIC in the recurrent/refractory setting.

AB - Allogeneic stem cell transplantation (SCT) with myeloablative conditioning is potentially curative therapy for myeloma, but is reportedly associated with a high risk of nonrecurrence mortality (NRM). Reduced-intensity conditioning (RIC) allows for the reduction of NRM, but the recurrence rate is increased. The role and timing of allogeneic SCT in the disease course remains controversial. To the authors' knowledge, there are limited data regarding the long-term outcome of RIC in the recurrent/refractory setting.

M3 - SCORING: Zeitschriftenaufsatz

VL - 116

SP - 3621

EP - 3630

JO - CANCER-AM CANCER SOC

JF - CANCER-AM CANCER SOC

SN - 0008-543X

IS - 15

M1 - 15

ER -